78715-56-7

Usage

Uses

Used in Pharmaceutical Industry:
Tetraethylfluoromethylene-diphosphonate is used as a reagent for the synthesis and design of T6PP inhibitors. The application reason is that T6PP catalyzes the hydrolysis of trehalose 6-phosphate to form trehalose, which is important in many fungal and bacterial pathogens. By inhibiting T6PP, Tetraethylfluoromethylene-diphosphonate can potentially help in the development of treatments for these pathogens.
Used in Antimicrobial Research:
Tetraethylfluoromethylene-diphosphonate is used as a research tool for studying the role of T6PP in the growth and survival of various microbial pathogens. The application reason is to better understand the mechanisms of these pathogens and to identify potential targets for new antimicrobial therapies.
Used in Drug Development:
Tetraethylfluoromethylene-diphosphonate is used as a starting material in the development of new drugs targeting T6PP. The application reason is to create novel compounds that can effectively inhibit T6PP, potentially leading to the development of new treatments for fungal and bacterial infections.

InChI:InChI=1/C9H21FO6P2/c1-5-13-17(11,14-6-2)9(10)18(12,15-7-3)16-8-4/h9H,5-8H2,1-4H3

Upstream product

• 75-69-4 trichlorofluoromethane 
• 2303-76-6 sodium diethyl phosphite 
• 1660-94-2 Tetraethyl methylenediphosphonate 
• 356-55-8 diethyl dichlorofluoromethylphosphonate 
• 814-49-3 diethyl chlorophosphate 
• 65094-25-9 diethyl dibromofluoromethylphosphonate 
• 53923-53-8 O,O-diethyl (chlorofluoromethyl)phosphonate 
• 220623-96-1 tetraethyllithiofluoromethylene bisphosphonate 

Downstream Products

• 135376-89-5 {[(8S,9R)-8,9-Bis-benzyloxy-2,4,10-trioxa-tricyclo[3.3.1.1^3,7]dec-(6E)-ylidene]-fluoro-methyl}-phosphonic acid diethyl ester 
• 10595-93-4 1-(fluoromethylene)-1,1-bisphosphonic acid 
• 1312032-35-1 tetraethyl (1-fluoro-2-(3-methoxyphenyl)ethane-1,1-diyl)bis(phosphonate) 
• 1312032-34-0 tetraethyl (2-(4-bromophenyl)-1-fluoroethane-1,1-diyl)bis(phosphonate) 
• 1312032-33-9 tetraethyl (1-fluoro-2-phenylethane-1,1-diyl)bis(phosphonate) 
• 1312032-36-2 methyl 4-(2,2-bis(diethoxyphosphoryl)-2-fluoroethyl)benzoate 
• 1309929-20-1 diethyl [3-benzenesulfinyl-1-(diethoxyphosphoryl)-1-fluoropropyl]phosphonate 
• 1309929-21-2 diethyl [3-benzenesulfonyl-1-(diethoxyphosphoryl)-1-fluoropropyl]phosphonate 
• 1268526-99-3 diethyl (E)-2-(5-amino-2-(4-methoxy-2-methylphenethyl)benzo[f][1,7]naphthyridin-8-yl)-1-fluorovinylphosphonate 
• 1192577-75-5 C₂₈H₄₁FN₃O₈PSi 

Relevant academic research and scientific papers

Convenient method for the synthesis and some transformations of the lithium salt of bis(diethoxyphosphoryl)fluoromethane

A convenient method was developed for the synthesis of the lithium salt of 1,1-bis(diethoxyphosphoryl)fluoromethane from available O,O-diethyl (chlorofluoromethyl)phosphonate, and some transformations of the resulting salt were studied.

Preparation and characterization of α-fluorinated-γ-aminophosphonates

Herein we would like to present a synthetic approach to series of α-fluorinated-γ-aminophosphonates, which were prepared by hydrogenolysis of (E)-α-fluorovinylphosphonates. The reaction conditions of hydrogenolysis in the presence of palladium on carbon h

RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE

The present disclosure relates to RNAi agents, for example, double stranded RNAi agents, able to inhibit HIF-2 alpha ( EPAS1 ) gene expression. Also disclosed are pharmaceutical compositions that include HIF-2 alpha RNAi agents and methods of use thereof. The HIF-2 alpha RNAi agents disclosed herein may be linked or conjugated to targeting ligands (such as compounds that have affinity for integrins, including alpha-v-beta-3 and alpha-v-beta-5 integrins) and pharmacokinetic (PK) enhancers, to facilitate the delivery to cells and tissues, including to clear cell renal cell carcinoma (ccRCC) cells and tumors. Delivery of compositions comprising the HIF-2 alpha RNAi agents in vivo provides for inhibition of HIF-2 alpha gene expression. The HIF-2 alpha RNAi agents can be used in methods of treatment of various diseases and disorders, including ccRCC.

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.

1-(Fluoroalkylidene)-1,1-bisphosphonic acids are potent and selective inhibitors of the enzymatic activity of Toxoplasma gondii farnesyl pyrophosphate synthase

α-Fluorinated-1,1-bisphosphonic acids derived from fatty acids were designed, synthesized and biologically evaluated against Trypanosoma cruzi, the etiologic agent of Chagas disease, and against Toxoplasma gondii, the agent responsible for toxoplasmosis, and also towards the target parasitic enzymes farnesyl pyrophosphate synthase of T. cruzi (TcFPPS) and T. gondii (TgFPPS). Interestingly, 1-fluorononylidene-1,1-bisphosphonic acid (compound 43) proved to be an extremely potent inhibitor of the enzymatic activity of TgFPPS at the low nanomolar range, exhibiting an IC50 of 30 nM. This compound was two-fold more potent than risedronate (IC50 = 74 nM) that was taken as a positive control. This enzymatic activity was associated with a strong cell growth inhibition against tachyzoites of T. gondii, with an IC50 value of 2.7 μM.

α- and β-Substituted phosphonate analogs of LPA as autotaxin inhibitors

Autotaxin (ATX) is an attractive pharmacological target due to its lysophospholipase D activity which leads to the production of lysophosphatidic acid (LPA). Blockage of ATX produced LPA by small molecules could be a potential anticancer chemotherapy. In our previous study, we have identified the two β-hydroxy phosphonate analogs of LPA (compounds f17 and f18) as ATX inhibitors. With this work, we investigated α- and β-substituted phosphonate analogs of LPA and evaluated them for ATX inhibitory activity. The stereochemistry of β-hydroxy phosphonates was also studied.

ORALLY AVAILABLE SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS AND ANTAGONISTS

The present invention relates to S1P analogs that have activity as S1Preceptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structure (I) wherein R11 is C5-C18 alkyl or C5-C18 alkenyl; Q is selected from the group consisting of C3-C6 optionally substituted cycloalkyl, C3-C6 optionally substituted heterocyclic, C3-C6 optionally substituted aryl C3-C6 optionally substituted heteroaryl and; R2 is selected from the group consisting of H, C1-C4 alkyl, (C1-C4 alkyl)OH and (C1-C4 alkyl)NH2; R23 is H or C1-C4 alkyl, and R15 is a phosphonate ester or a phosphate ester or a pharmaceutically acceptable salt or tautomer thereof.

ANALOGS OF LYSOPHOSPHATIDIC ACID AND METHODS OF MAKING AND USING THEREOF

Described herein are analogs of lysophosphatidic acid. Also described herein are methods of making and using analogs of lysophosphatidic acid.

Synthesis of α-fluorinated phosphonates from α -fluorovinylphosphonates: A new route to analogues of lysophosphatidic acid

(Matrix presented) A versatile, efficient method for the preparation of α-monofluoromethylene (-CHF-) phosphonates from α -fluorovinylphosphonate provides access to a class of lysophosphatidic acid (LPA) receptor-subtype agonists. In addition, sn-2 O-methylation of α-monofluoromethylene phosphonates using trimethylsilyldiazomethane generated sn-1-acyl, 2-O-methyl α-monofluoromethylene derivatives. Finally, a novel method for the selective etherification of 1,2-diols was developed and a new class of sn-1 O-methyl, 2-acyl α-monofluoromethylene LPA analogues was prepared.

The preparation of (EtO)2P(O)CFHZnBr and (EtO)2P(O)CFHCu and their utility in the preparation of functionalized α-fluorophosphonates

The organometallic reagent, (EtO)2P(O)CFHZnBr, was generated in situ in excellent yields via the reaction of (Eto)2P(O)CFHBr with zinc metal. Metathesis with Cu(I)Br gave (EtO)2P(O)CFHCu. The reagents exhibit excellent reactivity with substrates, such as allyl halides, alkynyl halides, vinyl halides, aryl halides and acyl or phosphoryl halides, and provide a useful one flask route to functionalized α-fluorophosphonates.